NCT06523868 Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Military Population: The Sentinel Study
| NCT ID | NCT06523868 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dana-Farber Cancer Institute |
| Condition | Cancer Diagnosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2025-03-31 |
| Primary Completion | 2027-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,500 participants in total. It began in 2025-03-31 with a primary completion date of 2027-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research study is to evaluate the possible benefits of an investigational, but commercially available Galleri multi-cancer early detection (MCED) blood test which is designed to detect many types of cancer early in veterans who have served in the military in active duty. The name of the screening blood test being studied is: -GRAIL Galleri MCED test
Eligibility Criteria
Inclusion Criteria: * Active-duty or National Guard/Reserves military service for four or more years * Age ≥ 45 * Received care at a VA facility within past 5 years * Able to sign informed consent * Willingness to travel to Dana-Farber Cancer Institute in Boston, MA, for diagnostic testing if screening test indicates possible malignancy Exclusion Criteria: * Individuals diagnosed with invasive malignancy within 3 years of enrollment (non- melanoma skin cancer is acceptable) * Individuals with evidence of symptomatic or active cancer requiring therapeutic intervention at the time of participation (hormone therapy for breast/prostate cancer is acceptable) * Individuals in the process of being evaluated for a clinical suspicion of cancer
Contact & Investigator
Elizabeth ODonnell, MD
PRINCIPAL INVESTIGATOR
Dana-Farber Cancer Institute
Frequently Asked Questions
Who can join the NCT06523868 clinical trial?
This trial is open to participants of all sexes, aged 45 Years or older, studying Cancer Diagnosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06523868 currently recruiting?
Yes, NCT06523868 is actively recruiting participants. Contact the research team at elizabeth_odonnell@dfci.harvard.edu for enrollment information.
Where is the NCT06523868 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT06523868 clinical trial?
NCT06523868 is sponsored by Dana-Farber Cancer Institute. The principal investigator is Elizabeth ODonnell, MD at Dana-Farber Cancer Institute. The trial plans to enroll 1,500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.